Related Experiment Video
Updated: May 20, 2026

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
Published on: July 6, 2015
Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to
Martine Besouw1, Albert Tangerman, Elisabeth Cornelissen
1Department of Pediatric Nephrology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. martine.besouw@uzleuven.be
Abstract:
Halitosis due to dimethylsulfide (DMS) generation is a major side effect of cysteamine in the treatment of cystinosis. Recently, an enteric coated formulation of cysteamine bitartrate (RP103) administered twice daily was demonstrated to be non-inferior for lowering WBC cystine levels compared to the non-enteric coated formulation (Cystagon®), administered 4 times per day. Since both formulations had different pharmacokinetic profiles, we compared DMS breath levels after administration of either RP103 or Cystagon® in four cystinosis patients. Although cysteamine areas under the curve (AUCs) were comparable, AUC of DMS was lower after the administration of RP103 compared to Cystagon®. This observation is of importance in cystinosis patients, since halitosis hampers compliance with cysteamine therapy.
More Related Videos
06:57The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
10:18Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells
Published on: June 13, 2019
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Urologic Endoscopic Procedure: Cystoscopic Examination